Allergan Slaps Peers, Self With Pricing Gauntlet
Admirable promises buck the industry but will make business more challenging.
This article is for subscribers only.
Because of its price hikes and highly acquisitive nature, Allergan has often been grouped with widely criticized specialty pharma peers such as Valeant.
That may be about to change: Allergan CEO Brent Saunders promised in a blog post on Tuesday that the company would limit future price hikes, in response to widespread criticism of the drug industry's practices. Saunders echoed some of those criticisms, saying companies that take predatory price increases have broken a "social contract" with patients and the public.